Open Payments

KENT SMITH

Type
Physician · Allopathic & Osteopathic Physicians / Family Medicine
Where
Roosevelt, UT
NPI
1588625479
Received
$12,250 in 9 records, 2019 to 2024 ($150 general, $12,100 research)
As principal investigator
$266,744 of research payments to others in 41 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment1$18
2023General payment1$18
2022General payment2$31
2021General payment2$28
2020General payment1$16
2020Research payment1$12,100
2019General payment1$37

By company

CompanyRecordsAmountYears
Eli Lilly and Company1$12,1002020
GE HEALTHCARE1$372019
PFIZER INC.2$312021–2023
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.1$182022
ABBVIE INC.1$182024
Intercept Pharmaceuticals, Inc.1$162020
Abbott Laboratories1$162021
Medtronic, Inc.1$122022

By nature of payment

NatureRecordsAmount
Research payment1$12,100
Food and Beverage8$150

Records

DateCompanyAmountNatureFormProductStudyYear
2024-02-07ABBVIE INC.$18Food and BeverageIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCE2024
2023-09-19PFIZER INC.$18Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2023
2022-08-24BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$18Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PRIMARY CARE2022
2022-01-30Medtronic, Inc.$12Food and BeverageIn-kind items and servicesINPEN SMART INSULIN DELIVERY SYSTEM Device, Continuous Glucose Monitoring2022
2021-05-12Abbott Laboratories$16Food and BeverageIn-kind items and servicesFreeStyle Libre 2 Device, Diabetes Care2021
2021-04-16PFIZER INC.$12Food and BeverageIn-kind items and servicesXELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT2021
2020-08-12Intercept Pharmaceuticals, Inc.$16Food and BeverageIn-kind items and servicesOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY2020
2020-06-15Eli Lilly and Company$12,100Research paymentCash or cash equivalentA PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE E2020
2019-05-29GE HEALTHCARE$37Food and BeverageCash or cash equivalent2019

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2024-03-01Celgene CorporationVelocity Clinical Research$489Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease2024
2023-12-19Seres Therapeutics, Inc.VELOCITY CLINICAL RESEARCH INC$7,913ECOSPOR IV: An Open-Label Extension of Study SERES-012 and Open-Label Program for Evaluating SER-109 in Subjects With Re2023
2023-10-03Celgene CorporationVelocity Clinical Research$3,000Ph III Yellowstone CD Maintenance (RPC01-3203) - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled St2023
2023-10-03Celgene CorporationVelocity Clinical Research$3,000PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202)2023
2023-10-03Celgene CorporationVelocity Clinical Research$3,000Ph III Yellowstone CD OLE (RPC01-3204) - A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderat2023
2023-09-01Celgene CorporationWestern Michigan University$3,092PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201)2023
2023-08-28Eli Lilly and CompanyVELOCITY CLINICAL RESEARCH INC$480A PHASE 3 MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO- AND ACTIVE- CONTROLLED TREAT-THROUGH STUDY TO EVALUATE THE EFFICA2023
2023-07-01Celgene CorporationWestern Michigan University$4,638PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202)2023
2022-02-23Eli Lilly and CompanyKENDALL REGIONAL MEDICAL CENTER$66A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE E2022
2021-10-22IRONWOOD PHARMACEUTICALS, INCVELOCITY CLINICAL RESEARCH - SALT LAKE CITY - GUT WHISPERER - ERN - PPDS$7,832C3718-3022021
2021-09-17IRONWOOD PHARMACEUTICALS, INCVELOCITY CLINICAL RESEARCH - SALT LAKE CITY - GUT WHISPERER - ERN - PPDS$1,200C3718-3022021
2021-09-08IRONWOOD PHARMACEUTICALS, INCVELOCITY CLINICAL RESEARCH - SALT LAKE CITY - GUT WHISPERER - ERN - PPDS$74C3718-3022021
2021-09-08IRONWOOD PHARMACEUTICALS, INCVELOCITY CLINICAL RESEARCH - SALT LAKE CITY - GUT WHISPERER - ERN - PPDS$1,000C3718-3022021
2021-09-08IRONWOOD PHARMACEUTICALS, INCVELOCITY CLINICAL RESEARCH - SALT LAKE CITY - GUT WHISPERER - ERN - PPDS$200C3718-3022021
2021-05-07IRONWOOD PHARMACEUTICALS, INCVELOCITY CLINICAL RESEARCH - SALT LAKE CITY - GUT WHISPERER - ERN - PPDS$884C3718-3022021
2021-05-05IRONWOOD PHARMACEUTICALS, INCVELOCITY CLINICAL RESEARCH - SALT LAKE CITY - GUT WHISPERER - ERN - PPDS$150C3718-3022021
2021-02-23Eli Lilly and CompanyKENDALL REGIONAL MEDICAL CENTER$752A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE E2021
2021-02-08Eli Lilly and CompanyVELOCITY CLINICAL RESEARCH INC$22,151A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE E2021
2020-11-25IRONWOOD PHARMACEUTICALS, INCADVANCED CLINICAL RESEARCH - GUT WHISPERER- ERN-PPDS$91C3718-3022020
2020-11-19Eli Lilly and CompanyKENDALL REGIONAL MEDICAL CENTER$581A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE E2020
2020-09-09IRONWOOD PHARMACEUTICALS, INCADVANCED CLINICAL RESEARCH - GUT WHISPERER- ERN-PPDS$600C3718-3022020
2020-09-04IRONWOOD PHARMACEUTICALS, INCADVANCED CLINICAL RESEARCH - GUT WHISPERER- ERN-PPDS$5,113C3718-3022020
2020-09-04IRONWOOD PHARMACEUTICALS, INCADVANCED CLINICAL RESEARCH - GUT WHISPERER- ERN-PPDS$4,534C3718-3022020
2020-07-24IRONWOOD PHARMACEUTICALS, INCADVANCED CLINICAL RESEARCH - GUT WHISPERER- ERN-PPDS$36C3718-3022020
2020-07-24IRONWOOD PHARMACEUTICALS, INCADVANCED CLINICAL RESEARCH - GUT WHISPERER- ERN-PPDS$148C3718-3022020
2020-07-15IRONWOOD PHARMACEUTICALS, INCADVANCED CLINICAL RESEARCH - GUT WHISPERER- ERN-PPDS$8,373C3718-3022020
2020-05-29Eli Lilly and CompanyAdvanced Clinical Research Inc$16A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE E2020
2020-05-20IRONWOOD PHARMACEUTICALS, INCADVANCED CLINICAL RESEARCH - GUT WHISPERER- ERN-PPDS$20,942C3718-3022020
2020-02-26IRONWOOD PHARMACEUTICALS, INCADVANCED CLINICAL RESEARCH - GUT WHISPERER- ERN-PPDS$3,409C3718-3022020
2020-02-03IRONWOOD PHARMACEUTICALS, INCADVANCED CLINICAL RESEARCH - GUT WHISPERER- ERN-PPDS$5,040C3718-3022020
2019-12-20IRONWOOD PHARMACEUTICALS, INCAdvanced Clinical Research Inc$1,101C3718-3022019
2019-12-02IRONWOOD PHARMACEUTICALS, INCAdvanced Clinical Research Inc$19,201C3718-3022019
2019-11-06IRONWOOD PHARMACEUTICALS, INCAdvanced Clinical Research Inc$148C3718-3022019
2019-10-09IRONWOOD PHARMACEUTICALS, INCAdvanced Clinical Research Inc$59C3718-3022019
2019-10-09IRONWOOD PHARMACEUTICALS, INCAdvanced Clinical Research Inc$26C3718-3022019
2019-09-18IRONWOOD PHARMACEUTICALS, INCAdvanced Clinical Research Inc$16,279C3718-3022019
2019-07-24IRONWOOD PHARMACEUTICALS, INCAdvanced Clinical Research Inc$52,712C3718-3022019
2019-05-17IRONWOOD PHARMACEUTICALS, INCAdvanced Clinical Research Inc$56,425C3718-3022019
2019-04-05IRONWOOD PHARMACEUTICALS, INCAdvanced Clinical Research Inc$52C3718-3022019
2019-03-20IRONWOOD PHARMACEUTICALS, INCAdvanced Clinical Research Inc$10,426C3718-3022019
2019-02-08IRONWOOD PHARMACEUTICALS, INCAdvanced Clinical Research Inc$1,500C3718-3022019

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Duchesne CountyRoosevelt city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Roosevelt, UT, county Duchesne County, UT, state Utah; placed by its city name.

MeasurePlace (city or town)
Roosevelt, UT
County
Duchesne County, UT
State
Utah
Population B010037,07820,1853,392,331
Population, 2020 census P16,74719,5963,271,616
Median age B0100228.034.132.0
Under 18 B0100134.8%32.2%27.8%
65 and over B010018.6%13.0%11.9%
Households B110012,3276,8781,124,822
Foreign born B050025.7%3.4%8.9%
Median household income B19013$76,456$78,445$95,166
Median family income B19113$87,313$89,486$109,675
Per capita income B19301$33,600$32,622$40,873
Poverty rate B1700115.9%11.8%8.5%
Unemployment rate B230256.1%4.3%3.6%
Civilian labor force B230253,1678,8171,778,106
Mean commute (minutes) B0801315.021.122.1
Bachelor's degree or higher B1500322.6%18.5%37.7%
Housing units B250012,5669,0281,223,468
Owner-occupied B2500367.0%78.9%70.2%
Renters B2500333.0%21.1%29.8%
Median home value B25077$282,500$283,700$489,400
Median gross rent B25064$977$1,009$1,496
White, not Hispanic B0300278.4%84.8%74.7%
Black B030020.1%0.1%1.1%
Hispanic or Latino B0300210.9%7.5%15.9%
Asian B030020.8%0.5%2.4%
American Indian and Alaska Native B030024.7%3.3%0.6%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Roosevelt, UT.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.